Withdrawals due to adverse events · acute gout
Non‐selective NSAIDs probably leads to higher withdrawals due to adverse events compared with selective cyclo‐oxygenase‐2 inhibitors (moderate certainty).
1 finding from 1 review
RR 2.34 [1.33, 4.14]
Studies not reported
Moderate
Total adverse events · acute gout
Non‐selective NSAIDs probably leads to higher total adverse events compared with selective cyclo‐oxygenase‐2 inhibitors (moderate certainty).
1 finding from 1 review
RR 1.94 [1.36, 2.78]
Studies not reported
Moderate
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Swelling (mean) · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Treatment failure (escalation of respiratory therapy to NIV, NIPPV or invasive ventilation) Measured up to 28 days · adults in the ICU, requiring respiratory support
HFNC may leads to lower treatment failure (escalation of respiratory therapy to NIV, NIPPV… compared with standard oxygen therapy (low certainty).
1 finding from 1 review
In‐hospital mortality (up to 90 days; included studies reported in‐hospital mortality, and mortality up to 28 days and up to ICU discharge) · adults in the ICU, requiring respiratory support
HFNC showed no clear difference in in‐hospital mortality (up to 90 days; included studies reported… compared with standard oxygen therapy (moderate certainty).
1 finding from 1 review
Adverse events Respiratory infection (pneumonia) Nasal mucosa or skin trauma · adults in the ICU, requiring respiratory support
HFNC showed no clear difference in adverse events Respiratory infection (pneumonia) Nasal mucosa or… compared with standard oxygen therapy (moderate certainty).
1 finding from 1 review
Duration of ICU stay · adults in the ICU, requiring respiratory support
1 finding from 1 review
Respiratory effects: PaO2/FiO2 ratio up to 24 hours after initiation of therapy · adults in the ICU, requiring respiratory support
1 finding from 1 review
Comfort · adults in the ICU, requiring respiratory support
2 findings from 1 review
Treatment failure (death or use of additional ventilatory support) · preterm infants with respiratory distress for initial respiratory support
It is very uncertain whether CPAP changes treatment failure (death or use of additional ventilatory support) compared with supplemental oxygen (very low certainty).
1 finding from 1 review
Use of assisted ventilation · preterm infants with respiratory distress for initial respiratory support
It is very uncertain whether CPAP changes use of assisted ventilation compared with supplemental oxygen (very low certainty).
1 finding from 1 review
All‐cause mortality · preterm infants with respiratory distress for initial respiratory support
CPAP probably leads to lower mortality compared with supplemental oxygen (moderate certainty).
1 finding from 1 review
Pneumothorax · preterm infants with respiratory distress for initial respiratory support
CPAP may leads to higher pneumothorax occurring after allocation compared with supplemental oxygen (low certainty).
1 finding from 1 review
Need for mechanical ventilation · patients with the management of transient tachypnea of the newborn
It is very uncertain whether non‐invasive respiratory support changes need for mechanical ventilation compared with supplemental oxygen or no treatment (very low certainty).
1 finding from 1 review
All‐cause mortality · patients with the management of transient tachypnea of the newborn
It is very uncertain whether non‐invasive respiratory support changes all‐cause mortality compared with supplemental oxygen or no treatment (very low certainty).
1 finding from 1 review
Length of hospital stay · patients with the management of transient tachypnea of the newborn
1 finding from 1 review
Duration of tachypnea, defined as hours with respiratory rate greater than 60 breaths per minute · patients with the management of transient tachypnea of the newborn
1 finding from 1 review
Exacerbations · Adults (aged 40 or over) with COPD presenting with 1 or more exacerbations in the previous year. The 2 larger studies (Albert 2011; Sethi…
Antibiotics probably leads to lower number of people with one or more exacerbations WMD of compared with placebo (moderate certainty).
1 finding from 1 review
Annual Exacerbation Rates · Adults (aged 40 or over) with COPD presenting with 1 or more exacerbations in the previous year. The 2 larger studies (Albert 2011; Sethi…
Antibiotics probably leads to lower rate of exacerbation per patient/year WMD of compared with placebo (moderate certainty).
1 finding from 1 review